COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact

Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VE(DIS)). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VE(SUSC)) or development of symptoms after infection (VE(SYMP)). We aim to assess and com...

Descripción completa

Detalles Bibliográficos
Autores principales: Swan, David A., Bracis, Chloe, Janes, Holly, Moore, Mia, Matrajt, Laura, Reeves, Daniel B., Burns, Eileen, Donnell, Deborah, Cohen, Myron S., Schiffer, Joshua T., Dimitrov, Dobromir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324774/
https://www.ncbi.nlm.nih.gov/pubmed/34330945
http://dx.doi.org/10.1038/s41598-021-94719-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324774/
https://www.ncbi.nlm.nih.gov/pubmed/34330945
http://dx.doi.org/10.1038/s41598-021-94719-y

Ejemplares similares